Hims and other telehealth firms make finasteride easy to get and don’t have to disclose side effects in ads.

RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Hims & Hers Health has called time on Apostrophe, its personalised acne treatments business. The San Francisco-based ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, the company will soon have to halt sales of its cheaper alternative.

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Certainly Hims & Hers will have to deal with strong competition (and it already is), but will it be easily disrupted? In my opinion, no. There are some moats that protect it. Its brand is already ...

Bloomberg / Contributor / Getty Images Shares of Hims & Hers Health (HIMS) plunged in late trading Monday after the company reported falling margins as costs rose, overshadowing better-than ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...